Delandistrogene moxeparvovec not checked

Sarepta Therapeutics, Inc. · SRP-9001

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 4 trial completes
Trials
3 active
5 in total · 4 in the EU
Targets
—
None known yet

What this is

How it works
A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
Tested for
Duchenne Muscular Dystrophy
Main trialPhase 4
“The primary objective of this study is to evaluate acute liver injury (ALI) rates associated with ELEVIDYS with the addition of sirolimus as an adjunct prophylactic immunosuppression agent.”In the company’s words, NCT07542314 on ClinicalTrials.gov
Other names
SRP-9001 · ELEVIDYS

Other drugs for Duchenne Muscular Dystrophy

All 23 drugs for Duchenne Muscular Dystrophy

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 31 Aug 2027 Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
Phase 1Terminated 10 Oct 2025 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
Phase 3Authorised not given A Phase 3, Multinational, Long-Term Follow-Up Study to Evaluate Safety and Efficacy in Subjects Who Have Previously Received SRP-9001 in a Clinical Study (EXPEDITION)
Phase 2Authorised not given A TWO-PART, OPEN-LABEL SYSTEMIC GENE DELIVERY STUDY TO EVALUATE THE SAFETY AND EXPRESSION OF RO7494222 (SRP‑9001) IN SUBJECTS UNDER THE AGE OF FOUR WITH DUCHENNE MUSCULAR DYSTROPHY
Phase 3Halted not given A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy (ENVISION)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Delandistrogene moxeparvovec

Following is part of Solo: you see every change to Delandistrogene moxeparvovec the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in